Get started
Author

Д. И. Шихбабаева

Observed names: D I Shikhbabaeva, D. I. Shikhbabaeva, D. Shikhbabaeva, Dgariat I. Shikhbabaeva, Dzhariiat I. Shikhbabaeva, Д.И. Шихбабаева, Шихбабаева Д.И.
Institution: Botkin Hospital
Observed institutions: Imperial College Healthcare NHS Trust, Hammersmith Hospital, Botkin Hospital, Russian Research Institute of Hematology and Transfusiology, City Clinical Hospital, Hopital Universitaire Habib Bourguiba
ORCID: 0000-0002-1384-1621
Observed ORCID: 0000-0002-1384-1621
OpenAlex ID: A5011470882
Development and Validation Results of the Russian MPN10 Form for Symptom Assessment in Patients with Myeloproliferative Neoplasms Compliant with International Recommendations
2020 · T. I. Ionova, O.Yu. Vinogradova, et al. · Clinical oncohematology · 7
PDF
Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy
2016 · K. M. Abdulkadyrov, Vasilii Anatol’evich Shuvaev, et al. · Clinical oncohematology · 7
PDF
Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study
2023 · O. Yu. Vinogradova, D. I. Shikhbabaeva, et al. · Oncohematology · 4
PDF
Primary Immune Thrombocytopenia and Thrombopoietin Receptor Agonists: Feasibilities of Treatment Discontinuation upon Achieving Stable Complete Platelet Response
2023 · O. Yu. Vinogradova, M. M. Pankrashkina, et al. · Clinical oncohematology · 3
PDF
Characteristics of regional epidemiological indicators of chronic myeloproliferative neoplasms
2025 · O. Yu. Vinogradova, A. L. Neverova, et al. · Oncohematology · 2
PDF
Possibilities of targeted therapy for myelofibrosis: Moscow experience
2022 · O. Yu. Vinogradova, M. M. Pankrashkina, et al. · Oncohematology · 2
PDF
Treatment opportunities for refractory immune thrombocytopenia
2024 · M. M. Pankraskina, O. Yu. Vinogradova, et al. · MD-Onco · 1
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
2024 · O. Yu. Vinogradova, M. M. Pankraskina, et al. · Oncohematology · 1
PDF
Long-term dynamics of epidemiological characteristics of some chronic leukemia and lymphoma in Moscow before, during and after the pandemic of the new coronavirus infection COVID-19. Epidemiologic study
2024 · Olga Yu. Vinogradova, Mikhail V. Chernikov, et al. · Journal of Modern Oncology · 1
PDF
Targeted therapy for advanced forms of systemic mastocytosis in real clinical practice
2023 · D. I. Shikhbabaeva, O. Yu. Vinogradova, et al. · Oncohematology · 1
PDF
Contemporary Interpretations of Ophthalmological Manifestations of Chronic Myeloproliferative Neoplasms
2023 · Larisa K. Moshetova, Lidia B. Egoryan, et al. · Annals of the Russian academy of medical sciences · 1
PDF
Pb2174 Epidemiology of Multiple Myeloma (mm) in Moscow (russia)
2019 · V. Ptushkin, O. Vinogradova, et al. · HemaSphere · 1
Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia
2018 · V. A. Shuvaev, Ol’ga Yur’evna Vinogradova, et al. · Clinical oncohematology · 1
PDF
Molecular Genetic Markers and Clinical Characteristics of Essential Thrombocythemia
2017 · Anastasiya Andreevna Zhernyakova, I. S. Martynkevich, et al. · Clinical oncohematology · 1
PDF
[Time course of changes in iron metabolic and oxidative-antioxidative system parameters in patients with acute myeloid leukemia].
2013 · S V Gritsaev, D I Shikhbabaeva, et al. · PubMed · 1
Применение агонистов рецептора тромбопоэтина при резистентных формах иммунной тромбоцитопении
2026 · М.М. Панкрашкина, О.Ю. Виноградова, et al. · Тромбоз гемостаз и реология
Genetic features of indolent and advanced forms of systemic mastocytosis
2025 · D. I. Shikhbabaeva, O. Yu. Vinogradova, et al. · Oncohematology
PDF
Primary and secondary myelofibrosis: ophthalmological manifestations at onset and during therapy
2025 · O. Yu. Vinogradova, L. B. Egoryan, et al. · Oncohematology
Genetic Aspects Classical Ph-negative Myeloproliferative Neoplasms (Literature Review)
2024 · М.А. Мурзабекова, Я.М. Марченко, et al. · Гематология Трансфузиология Восточная Европа
PDF
Central Retinal Vein Occlusion as the Debut of a Chronic Myeloproliferative Neoplasm
2024 · L. K. Moshetova, L. B. Egoryan, et al. · Ural Medical Journal
Materials of the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” (March 15–16, 2019; National Research Center for Hematology, Moscow)
2024 · A. L. Melikyan, A. G. Turkina, et al. · Clinical oncohematology
PDF
Efficacy of the combination of venetoclax and hypomethylating agents in the treatment of patients with primary, relapsed and/or refractory acute myeloid leukemia
2022 · E. V. Usikova, K. D. Kaplanov, et al. · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH)
PDF
Ps1183 the Potential Impact of Switch to Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Chronic Phase Who Had No Optimal Response to 3 Months of Initial Imatinib Therapy
2019 · O. Vinogradova, M. Pankrashkina, et al. · HemaSphere
Ps1106 a Retrospective Analysis of Immune Thrombocytopenia Patients Treatment Results After Sequential Switching of Thrombopoietic Receptor‐agonists
2019 · V. Ptushkin, O. Vinogradova, et al. · HemaSphere
Pf336 Evaluation of Thrombopoietin‐receptor Agonists (tpo‐ras) «stop‐therapy» in Idiopathic Thrombocytopenic Purpura (itp)
2019 · O. Vinogradova, M. Pankrashkina, et al. · HemaSphere
Works count: 36
Citation count: 34
H-index: 3
I10-index:
Year
Topic
Type